ADVANCED SOLID TUMORS
Clinical trials for ADVANCED SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lifeline for cancer patients: rollover study extends access to promising drug
Disease control Not yet recruitingThis study offers continued access to the experimental drug RVU120 for up to 10 adults with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from it in an earlier study. Participants must have completed at least 5 tre…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New hope for Hard-to-Treat cancers: drug targets RAS mutations
Disease control Not yet recruitingThis study tests an experimental drug called BPI-572270 in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participan…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:30 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors that have specific KRAS mutations (G12S or G12C) and no standard curative options. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 participants will …
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated May 26, 2026 08:27 UTC
-
New gene therapy targets advanced cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called KXV01 TCR Lentinvivo in 30 people with advanced solid tumors that have not responded to standard therapies. The treatment uses a virus to deliver cancer-fighting genes into the body. The main goals are to check safety and find t…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 26, 2026 08:26 UTC
-
New hope for rare cancers: china launches innovative drug trial
Disease control Not yet recruitingThis study tests new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants must have tried standard treatments or have no standard options. The goal is to see if these treatments are safe and shrink tumors, usi…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 26, 2026 08:24 UTC
-
Experimental combo aims to boost immune attack on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage study is testing a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—in about 60 people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and see if the combination can …
Matched conditions: ADVANCED SOLID TUMORS
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 26, 2026 08:22 UTC
-
New drug combo aims to shrink advanced tumors
Disease control Not yet recruitingThis study tests a new drug called QLS5132 given with other cancer treatments for people with advanced solid tumors, including stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination can shrink tumors. About 626 participants will…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New gene therapy trial targets hard-to-treat cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. Participants receive a single infusion of genetically modified…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New cell therapy GK01 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase trial tests an experimental cell therapy called GK01 in 15 people with advanced solid tumors (like stomach or lung cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will als…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Immune cells harvested from Patients' own tumors could fight advanced cancer
Disease control Not yet recruitingThis study tests an experimental therapy called GT307, made from a patient's own tumor-fighting immune cells. It is for people with advanced solid tumors (like cervical, melanoma, or lung cancer) that have spread or come back after standard treatment. The main goals are to see if…
Matched conditions: ADVANCED SOLID TUMORS
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Could your own immune cells fight advanced cancer? new trial launches
Disease control Not yet recruitingThis early-phase study tests whether a personalized therapy using a patient's own immune cells can safely control advanced solid tumors like lung, liver, colorectal, and breast cancers. Researchers will take blood, grow special immune cells in a lab, and infuse them back to help …
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for advanced cancer: SKB565 trial launches
Disease control Not yet recruitingThis study tests a new drug called SKB565 in 180 adults aged 18-75 with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The trial has three stages: starting with low doses, then expanding…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New drug targets stomach and pancreatic cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new drug called LCB02A in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attack cancer cells that have a specific protein (CLDN18.2) on their surface. The study will first find …
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New hope for advanced cancer: ALK-N001 enters human trials
Disease control Not yet recruitingThis study tests a new injectable drug, ALK-N001, in 190 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing, and to check its safety and how the body processes it. Participan…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 19, 2026 11:49 UTC
-
New cell shot targets tough tumors in early trial
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called GK01 in 10 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and how the body handles the therapy, while also looking for signs of tumor shrinkage. Participants…
Matched conditions: ADVANCED SOLID TUMORS
Phase: EARLY_PHASE1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests two experimental drugs, IMM2510 and IMM01, given together to adults with advanced solid tumors that have not responded to at least one prior treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow their growth. About 104 pa…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New hope for advanced cancer patients: experimental drug XNW34017 enters human trials
Disease control Not yet recruitingThis study tests a new drug called XNW34017 in 150 people with advanced solid tumors who have run out of standard options. The goal is to see if the drug is safe and can shrink tumors. The trial has two phases: first finding the right dose, then testing that dose in more patients…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New targeted cancer therapy begins first human testing
Disease control Not yet recruitingThis is the first human study of an experimental cancer drug called M7437, which targets a specific protein found on certain tumor cells. The study will test the safety, side effects, and early effectiveness of M7437 in 138 people with advanced solid tumors that have stopped resp…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jan 26, 2026 13:59 UTC